These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18691475)

  • 1. Angiotensin receptor blockers: current status and future prospects.
    Ram CV
    Am J Med; 2008 Aug; 121(8):656-63. PubMed ID: 18691475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
    Pourdjabbar A; Lapointe N; Rouleau JL
    Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
    Lip GY; Frison L; Grind M
    J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
    Kalaitzidis R; Bakris G
    Postgrad Med; 2009 Mar; 121(2):77-88. PubMed ID: 19332965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
    Song JH; Cha SH; Hong SB; Kim DH
    J Hypertens Suppl; 2006 Mar; 24(1):S101-6. PubMed ID: 16601562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microalbuminuria, insulin resistance, diabetes, hypertension, and kidney function: the latest concepts in pathology and pharmacologic treatment.
    Barri YM; Palmer BF; Ram CV
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):34-45. PubMed ID: 19667709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
    Bakris GL; Weir MR
    Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology of the renin-angiotensin-system in atrial fibrillation].
    Heusch G; Schulz R
    Dtsch Med Wochenschr; 2006 Apr; 131(15):817-20. PubMed ID: 16607602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.